Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results PR Newswire ALISO VIEJO, Calif., Feb. 7, 2013 ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ --Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) Quarterly Financial Highlights oTotal company net revenues increased to $16.5 million, representing growth of 22% versus the previous quarter oGross and net NUEDEXTA® sales increased to $18.4 million and $14.9 million, respectively, representing growth of 19% and 20% versus the previous quarter oCash, cash equivalents, and restricted investments of $59.3 million as of December 31, 2012. "Avanir delivered another strong quarter of growth with record NUEDEXTA sales and prescriptions," said Keith A. Katkin, president and CEO of Avanir. "In addition, the clinical team has successfully executed our plan to move our next generation asset, AVP-786, through the first stage of the phase I clinical study, with encouraging results. With demonstrated success in the AVP-786 study, we now have two promising assets in clinical development, each of which has broad potential in a number of CNS indications." Fiscal 2013 First Quarter Results oTotal net revenues for the quarter ended December 31, 2012 were $16.5 million, compared with $7.2 million for the comparable quarter in fiscal 2012, representing 130% year-over-year growth. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®. oTotal operating expenses, excluding cost of sales and share-based compensation were $25.3 million in the first quarter of fiscal 2013, compared with $21.7 million in the comparable period in fiscal 2012. oCash used in operations was $12.7 million in the first quarter of fiscal 2013. oNet loss for the fiscal 2013 first quarter was $12.1 million, or $0.09 per share, compared with a net loss of $15.9 million, or $0.12 per share, for the same period in fiscal 2012. NUEDEXTA Revenue For the quarter ended December 31, 2012, the company reported NUEDEXTA gross and net revenue of $18.4 million and $14.9 million respectively. First quarter fiscal 2013 NUEDEXTA net revenue increased 20% over the previous quarter. Cash, Cash Equivalents & Marketable Securities As of December 31, 2013 Avanir had cash, cash equivalents and investments in securities totaling $59.3 million, including cash and cash equivalents of $56.9 million and restricted investments in securities of $2.4 million. Business Highlights oThe company reported its seventh consecutive quarter of record NUEDEXTA revenues and prescriptions oOver 13,000 cumulative patient years of exposure of NUEDEXTA in PBA across multiple neurologic conditions oThe company successfully completed the first stage of a two-stage pharmacokinetic study with AVP-786 oContinued clinical progress in three potential follow-on indications for AVP-923 in Alzheimer's disease, neuropathic pain, and Parkinson's disease oThe Michael J. Fox Foundation awarded the company a grant to study AVP-923 for the treatment of levodopa-induced-dyskinesia (LID) in Parkinson's disease (PD) Note to Investors: As previously announced, Avanir will hold a conference call to discuss fiscal 2013 first quarter financial results today, February 7, 2013, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1-866-783-2141 for domestic callers or +1-857-350-1600 for international callers, and entering passcode 51423033. Those interested in listening to the conference call live via the internet may do so by visiting http://ir.avanir.com. About AVP-786 AVP-786 is a novel compound developed through incorporation of deuterium into specific molecular positions of dextromethorphan. The compound maintains similar pharmacology to that of dextromethorphan, but is less susceptible to metabolism by the CYP2D6 enzyme. Avanir licensed exclusive worldwide rights to AVP-786 from Concert Pharmaceuticals, Inc. About AVP-923 AVP-923 is a combination of two well-characterized compounds, the active CNS ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist) plus low-dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan. AVP-923 is being studied in several ongoing clinical trials including agitation in Alzheimer's disease, neuropathic pain in Multiple Sclerosis, levodopa-induced dyskinesia in Parkinson's disease, and behavioral symptoms of autism. About NUEDEXTA NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown. NUEDEXTA Important Safety Information NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. NUEDEXTA and certain other medicines can interact, causing serious side effects. If you take certain drugs or have certain heart problems, NUEDEXTA may not be right for you. NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation should be conducted at baseline and 3-4 hours after the first dose. The most common adverse reactions are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence. NUEDEXTA may cause dizziness. These are not all the risks from use of NUEDEXTA. Please refer to full Prescribing Information at www.NUEDEXTA.com. About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com. Avanir® and NUEDEXTA® are registered trademarks owned by Avanir Pharmaceuticals, Inc. ^©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved. Forward Looking Statements Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new products domestically and internationally, obtaining additional indications, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. Avanir Investor & Media Contact Ian Clements, PhD email@example.com +1 (949) 389-6700 AVANIR PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS December 31, September 30, 2012 2012 (unaudited) (audited) ASSETS Current assets: Cash and cash equivalents $ 56,942,618 $ 69,778,406 Trade receivables, net 6,834,022 7,231,759 Inventories, net 378,244 415,475 Prepaid expenses and other current assets 4,085,903 2,434,590 Current portion of restricted investments 1,054,463 1,054,463 in marketable securities Total current assets 69,295,250 80,914,693 Restricted investments in marketable securities, 1,303,938 1,302,136 net of current portion Property and equipment, net 1,789,140 1,808,594 Non-current inventories, net 908,364 908,364 Other assets 665,159 1,078,009 TOTAL ASSETS $ 73,961,851 $ 86,011,796 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable, accrued expenses and other $ 14,324,457 $ 15,598,666 liabilities Deferred product revenues, net - - Current portion of note payble 4,949,972 2,162,263 Current portion of deferred royalty revenues 2,557,464 2,557,464 Total current liabilities 21,831,893 20,318,393 Accrued expenses and other liabilities, net of 869,722 666,179 current portion Note Payable 24,048,825 26,698,263 Deferred royalty revenues, net of current 1,017,247 1,491,854 portion Total liabilities 47,767,687 49,174,689 Total stockholders' equity 26,194,164 36,837,107 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 73,961,851 $ 86,011,796 AVANIR PHARMACEUTICALS, INC. CONDENSED STATEMENT OF OPERATIONS Three Months Ended December 31, 2012 2011 REVENUES Net product sales $ 14,879,262 $ 5,488,763 Revenues from royalties 1,626,010 1,676,120 Revenue from research grant 15,000 - services Total revenues 16,520,272 7,164,883 OPERATING EXPENSES Cost of product sales 838,129 309,803 Cost of research grant services 9,398 - Research and development 6,648,091 3,744,515 Selling and marketing 13,522,419 13,782,836 General and administrative 6,538,403 5,292,183 Total operating expenses 27,556,440 23,129,337 Loss from operations (11,036,168) (15,964,454) OTHER INCOME (EXPENSE) Interest income 19,331 14,291 Interest expense (1,059,245) - Other, net - 4,006 Net loss and comprehensive loss $ (12,076,082) $ (15,946,157) Basic and diluted net loss per share $ (0.09) $ (0.12) Basic and diluted weighted average 136,772,557 127,934,257 number of common shares outstanding SOURCE Avanir Pharmaceuticals, Inc. Website: http://www.avanir.com
Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
Press spacebar to pause and continue. Press esc to stop.